Craig Woods
-
-
ASU Skysong 1475 N. Scottsdale Rd Bldg 1; 361 Scottsdale, AZ 85257
-
Mail code: 9908Campus: Scottsdale
-
Craig Woods is a clinical researcher and business developer with over 20 years of experience in human and veterinary clinical trials, regulatory affairs (FDA, USDA), technology licensing, and pharmaceutical development. Craig joined the Institute for Future Health in June of 2021 to manage multi-institutional healthcare projects and aligning the resources and expertise of Arizona's public universities with the needs of external partners (hospitals, industry, etc.) with a focus on infectious disease and biosecurity challenges.
From 2015-2021, Craig was the Director of Midwestern University's Institute for Healthcare Innovation which managed Phase II-III clinical trials at University clinics and external hospitals, as well as veterinary clinical studies at the College of Veterinary Medicine. During this time, Craig served as a clinical investigator on infectious diseases (anti-infectives, SARS-CoV-2) and comparative medical studies in the areas of envenomation, oncology, neurology, orthopedics, and cardiovascular disease.
From 1998-2015, Craig was in the pharmaceutical industry with companies in the US, Mexico, and France focused on business development, regulatory affairs and R&D. During this time, he was responsible for leading due diligence and licensing negotiations for various pharmaceuticals, biologics, and medical devices. Craig also founded several start-up biomedical companies, leading the licensing, development and/or commercialization of first-in-class medical technologies. Craig's work in comparative ophthalmology and biomaterials led to the development and commercialization of a novel subscleral (suprachoroidal) glaucoma implant for humans.
From 1995-1998, Craig was in small animal clinical practice in Tucson, AZ and Fountain Hill, AZ, and remains a licensed veterinarian in Arizona.
Interests/Expertise:
- Research: infectious disease, biosecurity, drug development, and venoms & toxins.
- Clinical: study management, study documentation and protocol development.
- Business: contract design, negotiations, valuation models, and business strategy
- Regulatory: clinical research management and compliance (HIPAA, GCP, VICH, ICH)
- BS - Biology; University of Missouri (1987-1991)
- MS - Veterinary Anatomy; University of Missouri (1991-1995)
- DVM - Veterinary Medicine; University of Missouri (1991-1995)
- MBA - Business Administration; Arizona State University (2001-2003)
- Arizona Veterinary Medical License (1995-current)
Current Research Focus: My current areas of research are directed at establishing multi-disciplinary teams to address infectious diseases, zoonosis, and pathogen surveillance and improving biosecurity measures. In this capacity, I work with multiple stakeholders (e.g., academia, industry, healthcare networks, and government agencies) to address major healthcare challenges, identify funding mechanisms, and serve to manage (direct) the respective projects.
Active Projects (2023): (serving as PI or Co-I)
- Cardiac Amyloidosis Biomarkers - ASU and Mayo Clinic
- Vaccine Effectiveness - Centers for Disease Control and Prevention
- Avian Influenza Surveillance - Aegis Consortium; UA ASU collaboration
- Chemical & Biological Projects (confidential) - Department of Defense and Department of State
- Hyperspectral Analysis of Cancer Tissues
Prior Clinical Research:
- Comparative medicine and translational research (infectious diseases, ophthalmology, cardiology, orthopedics, pain management, and other therapeutic categories)
- Clinical trials (PII-PIV): overall management and logistics for interventional and observations human subjects research.
- Toxinology: pit viper envenomation and antivenom development.
- Witsil AJ, Wells RJ, Woods CW, and Rao S. 272 cases of rattlesnake envenomation in dogs: demographics and treatment including safety of F(ab’)2 antivenom. Toxicon. 2015 Oct Vol105: 19-26.
- Peterson ME, Woods CW, Seibold KE, and Schaer M. Confounding in study of antivenoms. J Am Vet Med Assoc. 2013 Dec 1;243(11):1516.
- Woods CW and Young DA. F(ab’)2 Antivenom: Clinical Safety in Dogs. J. Vet Em Crit Care, Oct 2011.
- Woods CW, Seibold K. Problems with Antivenom Study; Letter. J. Vet Em Crit Care, Oct 2010.
- Terry DE, Rees-Milton K, Smith P, Carran J, Pezeshki P, Woods CW, Greer P, Anastassiades TP. N-acylation of glucosamine modulates chondrocyte growth, proteoglycan synthesis, and gene expression. J Rheumatol. 2005 Sep; 32 (9):1775-86.
Human Clinical Studies (2020-2021)
- Testing the efficacy and safety of [drug] in patients with SARS-CoV-2; Role: Study Site Director
- Multiplexed in-solution serological test for SARS-CoV-2 and other respiratory pathogens; Role: Site Prinicipal Investigator
- SARS-CoV-2 longitudinal immunosurveillance of emergency room providers; Role: Co-Principal Investigator
- COVID-19 - secondary use and analysis of patient biospecimens; Role: Co-Principal Investigator
Scientific Abstracts and Oral Presentations
- Woods CW. Review: Veterinary Regenerative Medicine and Tissue Engineering. Oral Abstract. Tissue Engineering and Regenerative Medicine International Society Conference (TERMIS). Dec. 13, 2016
- Woods CW. Review: The Dog as a Translational Model for Envenomation. Oral Abstract. Venom Week 2016, Toxicon Volume 117, July 2016, Page 107.
- Wells R and Woods CW. F(ab’)2 Antivenom Treatment: A Retrospective Analysis of 180 Rattlesnake Envenomations in Dogs: Oral abstract - IVECCS September 2013, San Diego.
- Falcone K, Klaus J, Mulligan K, Woods CW: Retrospective Study of F(ab’)2 Antivenom in 61 Dogs and 15 Cats Envenomated by Arizona Rattlesnakes, Oral Abstract. IVECCS 2012.
- Woods CW. Anti-Endotoxin Effects and Pharmacology of the Immune Selective Anti-Inflammatory Derivatives. Venom Week 2012; Oral Abstract – Toxicon Volume 60(2), 2012.
- Seibold KE, Woods CW, and Wells RJ. F(ab’)2 Antivenom in Dogs Envenomated by Pit Vipers. Venom Week 2012; Oral Abstract – Toxicon Volume 60(2), 2012.
- Woods CW, Seibold KE, Wells RJ. Crotalidae Venom Levels in Dogs Before and After Administration of F(ab’)2 Antivenom. Venom Week 2012; Oral Abstract – Toxicon Volume 60(2), 2012.
- K. Seibold, C. Woods, R. Wells, M. Lagutchik, et al.B. Vasilopulos. Neutralizing effects of F(ab’)2 antivenom on serum pit viper venom levels in dogs. Oral Abstract. Nashville, TN. IVECCS 2011.
- Gingerich DA, and Woods, CW. T-cell Receptor Peptide Therapeutics for Feline Stomatitis; Oral Abstract, Am. Assoc. of Vet. Pharmacology and Therapeutics – 2011 Conference.
- K.Seibold, A. Reniker, R. Wells, M. Lagutchik, S. Johnson, D. Bordelon, M. Clare, M. Kaelble, R. Vasilopulous, and C. Woods; Evaluation of an Antivenom F(ab’)2 in 74 Dogs Envenomated by North American Pit Vipers. Abstract; San Antonio; IVECCS 2010.
- Woods, C, Godine, R and Huber B. apSTAR Cancer Laser: Review of Immunological Effects and Case Reports. Veterinary Cancer Society Mid-Year Meeting; 2010.
- Woods, CW. Use of TCR Peptides for Feline Stomatitis. 23rd Annual Veterinary Dental Forum: 2009.
- Woods, CW. Tissue Repair BioScaffold; Clinical Review. 23rd Annual Veterinary Dental Forum: 2009.
- Urbanz, J and Woods, CW. Effects of an Embryonic-like BioScaffold on Canine Indolent Ulcer. Abstract Presentation; Am. College of Vet. Ophthalmologists 2009; Chicago, IL.
- Roberts SW and Woods, CW. The Use of a Novel Porous Implant for Refractory Canine Glaucoma. Abstract Presentation; Am. College of Vet. Ophthalmologists Conference 2008; Boston, MA.
- Urbanz, J and Woods, CW. The Use of a Novel Biomaterial for Refractory Canine Dry Eye; 2006 Am. College of Veterinary Ophthalmologists Conference 2006.
- Howard Hughes Undergraduate Medical Fellowship (1989-1990)
- Veterinary Biomedical Research Fellowship (1991-1992)
ad hoc Reviewer
- Veterinary Anaesthesia and Analgesia
- Toxicon
- Journal of the American Veterinary Medical Association
Memberships
- Arizona Veterinary Medical Association (1995-present)
- American Veterinary Medical Association (1995-present)
- North American Society of Toxinology
- International Society of Toxinology
- Board of Directors - United Cerebral Palsy Foundation of Arizona
- Organizing Chair - Venom Week VIII 2022
- Veterinary Co-Chair - Venom Week V and 17th Annual World Toxinology Society Conference
- Woods Consulting, LLC - biomedical research and regulatory services
- 2022: Organizing Chair – Venom Week VIII International Medical & Scientific Symposium
- 2012: Veterinary Co-Chair - Venom Week & 17th Annual World Toxinology Society
- 2021-Board Member, Central Arizona United Cerebral Palsy Foundation
- 2017-2021: Board Delegate (alternate) Arizona Bioindustry Association
- 2017-2021: Independent Board Member, Chelation Partners, Inc.
- 2010-2013: Scientific Advisory Board, iSTAR Medical
- 2011-2013: Business Advisor, Advanced Anesthesia Specialists, LLC
- 1998-1999: Board Member, Arizona Bioindustry Cluster
- Vetoquinol SA (Manager of Business Development of the Americas)
- BioVeteria Life Sciences, LLC (US General Manager and Regulatory Official)
- Vet-Stem, Inc. (Vice President of Marketing)
- Farnam Companies, Inc. (Vice President of Business Development)